[Absence of cutaneous complications following extravasation of pegylated liposomal doxorubicin].
Capitain
O
O
Lortholary
A
A
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects*; D003875:Drug Eruptions / Q000628:therapy*; D004487:Edema / Q000139:chemically induced / Q000628:therapy; D004890:Erythema / Q000139:chemically induced / Q000628:therapy; D005119:Extravasation of Diagnostic and Therapeutic Materials / Q000150:complications*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008081:Liposomes; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects*
D008081:Liposomes; D011092:Polyethylene Glycols; D004317:Doxorubicin